NO20062061L - Nye substituerte, 4-amino-tiazolo[4,5-D]pyriminder, nyttige som kjemokinreseptorantagonister, ESP. CX3CR1 - Google Patents
Nye substituerte, 4-amino-tiazolo[4,5-D]pyriminder, nyttige som kjemokinreseptorantagonister, ESP. CX3CR1Info
- Publication number
- NO20062061L NO20062061L NO20062061A NO20062061A NO20062061L NO 20062061 L NO20062061 L NO 20062061L NO 20062061 A NO20062061 A NO 20062061A NO 20062061 A NO20062061 A NO 20062061A NO 20062061 L NO20062061 L NO 20062061L
- Authority
- NO
- Norway
- Prior art keywords
- receptor antagonists
- pyrimines
- cx3cr1
- thiazolo
- esp
- Prior art date
Links
- -1 4-amino-thiazolo [4,5-D] pyrimines Chemical class 0.000 title 1
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 title 1
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 title 1
- 229940122444 Chemokine receptor antagonist Drugs 0.000 title 1
- 239000002559 chemokine receptor antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000016192 Demyelinating disease Diseases 0.000 abstract 1
- 108010018976 Interleukin-8A Receptors Proteins 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0302667A SE0302667D0 (sv) | 2003-10-07 | 2003-10-07 | Novel Compounds |
| SE0302666A SE0302666D0 (sv) | 2003-10-07 | 2003-10-07 | Novel Compounds |
| PCT/SE2004/001421 WO2005033115A1 (en) | 2003-10-07 | 2004-10-05 | New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20062061L true NO20062061L (no) | 2006-07-03 |
Family
ID=34425473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20062061A NO20062061L (no) | 2003-10-07 | 2006-05-08 | Nye substituerte, 4-amino-tiazolo[4,5-D]pyriminder, nyttige som kjemokinreseptorantagonister, ESP. CX3CR1 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20070142386A1 (enExample) |
| EP (1) | EP1675862A1 (enExample) |
| JP (1) | JP2007507494A (enExample) |
| KR (1) | KR20060120014A (enExample) |
| AU (1) | AU2004278276B2 (enExample) |
| BR (1) | BRPI0415050A (enExample) |
| CA (1) | CA2541533A1 (enExample) |
| IL (1) | IL174508A0 (enExample) |
| MX (1) | MXPA06003792A (enExample) |
| NO (1) | NO20062061L (enExample) |
| WO (1) | WO2005033115A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9903544D0 (sv) | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
| GB2359551A (en) | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| GB0221828D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
| GB0328243D0 (en) | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Methods |
| WO2006046739A1 (ja) | 2004-10-29 | 2006-05-04 | Eisai R & D Management Co., Ltd. | 炎症性疾患治療剤 |
| US20090239882A1 (en) * | 2004-12-17 | 2009-09-24 | Astrazeneca Ab | Thiazolopyramidine Compounds for the Modulation of Chemokine Receptor Activity |
| AR053347A1 (es) | 2005-04-06 | 2007-05-02 | Astrazeneca Ab | Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos |
| UA90707C2 (en) | 2005-04-06 | 2010-05-25 | Астразенека Аб | Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives |
| PE20080145A1 (es) | 2006-03-21 | 2008-02-11 | Janssen Pharmaceutica Nv | Tetrahidro-pirimidoazepinas como moduladores de trpv1 |
| WO2008005303A2 (en) * | 2006-06-30 | 2008-01-10 | Janssen Pharmaceutica N.V. | Thiazolopyrimidine modulators of trpv1 |
| CA2664930A1 (en) * | 2006-09-29 | 2008-04-03 | Astrazeneca Ab | Novel 5,7-disubstituted[1,3]thiazolo[4,5-d]pyrimidin-2(3h)-amine derivatives and their use in therapy |
| TW200820973A (en) * | 2006-09-29 | 2008-05-16 | Astrazeneca Ab | Novel compounds 480 |
| WO2009078999A1 (en) | 2007-12-17 | 2009-06-25 | Janssen Pharmaceutica N.V. | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1 |
| US20090156598A1 (en) * | 2007-12-17 | 2009-06-18 | Lebsack Alec D | Imidazolopyrimidine modulators of TRPV1 |
| WO2009109616A2 (en) | 2008-03-07 | 2009-09-11 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Novel 1-benzil-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40 |
| PT2254869T (pt) * | 2008-03-07 | 2017-07-18 | Acraf | Novos derivados de 1-benzil-3-hidroximetilindazole e suas utilizações no tratamento de doenças com base na expressão de cx3cr1 e p40 |
| CN101959866B (zh) | 2008-03-07 | 2013-10-02 | 方济各安吉利克化学联合股份有限公司 | 1-苄基-3-羟基甲基吲唑衍生物及其在治疗基于mcp-1和cx3cr1表达的疾病中的用途 |
| JO3437B1 (ar) | 2009-10-30 | 2019-10-20 | Esai R & D Man Co Ltd | أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها |
| WO2012078633A2 (en) * | 2010-12-07 | 2012-06-14 | Philadelphia Health And Education Corporation, D/B/A Drexel University College Of Medicene | Methods of inhibiting metastasis from cancer |
| US8476301B2 (en) | 2011-09-13 | 2013-07-02 | Eisai R&D Management Co., Ltd. | Pyrrolidin-3-ylacetic acid derivative |
| TWI543975B (zh) * | 2011-09-13 | 2016-08-01 | Eisai R&D Man Co Ltd | Pyrrolidin-3-yl acetic acid derivatives |
| JP5872105B2 (ja) | 2013-03-12 | 2016-03-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピロリジン−３−イル酢酸誘導体の塩およびその結晶 |
| WO2014142086A1 (ja) * | 2013-03-13 | 2014-09-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピロリジン－３－イル酢酸誘導体およびピペリジン－３－イル酢酸誘導体 |
| US11267817B2 (en) | 2017-05-02 | 2022-03-08 | Drexel University | Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists |
| GB201811169D0 (en) | 2018-07-06 | 2018-08-29 | Kancera Ab | New compounds |
| KR20250086780A (ko) | 2022-10-19 | 2025-06-13 | 아스트라제네카 아베 | Cx3cr1 조절제로서의 2,4,6-삼중치환된 1,3,5-트리아진 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9802729D0 (sv) * | 1998-08-13 | 1998-08-13 | Astra Pharma Prod | Novel Compounds |
| SE9903544D0 (sv) * | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
| SE0101082D0 (sv) * | 2001-03-27 | 2001-03-27 | Astrazeneca Ab | Novel use |
| SE0101322D0 (sv) * | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | Novel compounds |
-
2004
- 2004-10-05 MX MXPA06003792A patent/MXPA06003792A/es unknown
- 2004-10-05 KR KR1020067006638A patent/KR20060120014A/ko not_active Withdrawn
- 2004-10-05 JP JP2006532235A patent/JP2007507494A/ja active Pending
- 2004-10-05 CA CA002541533A patent/CA2541533A1/en not_active Abandoned
- 2004-10-05 WO PCT/SE2004/001421 patent/WO2005033115A1/en not_active Ceased
- 2004-10-05 BR BRPI0415050-3A patent/BRPI0415050A/pt not_active IP Right Cessation
- 2004-10-05 US US10/575,534 patent/US20070142386A1/en not_active Abandoned
- 2004-10-05 EP EP04775512A patent/EP1675862A1/en not_active Withdrawn
- 2004-10-05 AU AU2004278276A patent/AU2004278276B2/en not_active Ceased
-
2006
- 2006-03-23 IL IL174508A patent/IL174508A0/en unknown
- 2006-05-08 NO NO20062061A patent/NO20062061L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005033115A1 (en) | 2005-04-14 |
| IL174508A0 (en) | 2006-08-01 |
| AU2004278276B2 (en) | 2007-10-18 |
| EP1675862A1 (en) | 2006-07-05 |
| US20070142386A1 (en) | 2007-06-21 |
| JP2007507494A (ja) | 2007-03-29 |
| AU2004278276A1 (en) | 2005-04-14 |
| MXPA06003792A (es) | 2006-06-14 |
| KR20060120014A (ko) | 2006-11-24 |
| CA2541533A1 (en) | 2005-04-14 |
| BRPI0415050A (pt) | 2006-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20062061L (no) | Nye substituerte, 4-amino-tiazolo[4,5-D]pyriminder, nyttige som kjemokinreseptorantagonister, ESP. CX3CR1 | |
| NO20050164L (no) | Nye quinuklidin-amid-derivater | |
| CA2523261A1 (en) | Fused pyrimidine derivatives with crf activity | |
| WO2003048164A3 (en) | Adenosine a2a receptor antagonists | |
| NO20055219L (no) | Nye forbindelser | |
| NO20075059L (no) | Nye forbindelser II 2-pyridinderivater som inhibitorer av neutrofil elastase | |
| MXPA04002338A (es) | Derivados de carbazol y su uso como antagonistas receptores del npy5. | |
| NO20045486L (no) | Nye forbindelser og deres anvendelse | |
| EP1416933B8 (en) | Substituted piperidines as modulators of the melanocortin receptor | |
| WO2007040438A3 (en) | Novel imidazo [4,5 -b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders | |
| NO20064166L (no) | Utvalgte CGRP-antagonister, deres fremstilling og deres anvendelse som medikanmenter | |
| NO20062335L (no) | Nye diazaspiroalkaner og deres anvendelse i behandlingen av CCR8 medierte sykdommer | |
| IL165264A (en) | Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases | |
| NO20062713L (no) | 2,6 bisheteroaryl-4-aminopyrimidiner som adenosin reseptor antagonister | |
| NO20071140L (no) | Nye piperidinderivater som histamin H3 reseptorligander for behandling av depresjon | |
| CA2468649A1 (en) | Adenosine a2a receptor antagonists | |
| BR0210122A (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo | |
| NO20054868L (no) | CaSr antagonist | |
| WO2004054973A3 (en) | Piperidine and pyrrolidine derivatives as antagonists of histamine h3 receptor | |
| DE602005007339D1 (de) | Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol | |
| NO20070837L (no) | Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer. | |
| MY140835A (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists | |
| WO2006007540A3 (en) | Piperidine derivatives as nk1 antagonists | |
| BRPI0519398A2 (pt) | compostos de piridina para o tratamento de doenÇas mediadas por prostaglandina | |
| DE60322680D1 (de) | Opioid-rezeptor-aktive 4-(3-hydroxyphenyl) oder 4-(3-alkoxyphenyl)-1,2,4-triazol-verbindungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |